Flufenamic Acid
Spécifications
530-78-9Numéro CAS
208-494-1Numéro CE
2-[3-(trifluoromethyl)anilino]benzoic acidNom IUPAC
C14H10F3NO2Formule chimique
281.23 g/molMasse molaire
flufenamic acid; 530-78-9; Arlef; Fluphenamic acid; Achless; 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid; N-(3-Trifluoromethylphenyl)anthranilic acid; Acido flufenamico; Flufenaminsaeure; Meralen; 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid; Acide flufenamique; 2-[3-(Trifluoromethyl)anilino]benzoic acid; CI 440; NSC-82699; Acidum flufenamicum; 2-[[3-(Trifluoromethyl)phenyl]amino]benzoic acid; CN-27,554; 3'-Trifluoromethyldiphenylamine-2-carboxylic acid; INF-1837; DTXSID7023063; Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-; Benzoic acid, 2-((3-(trifluoromethyl)phenyl)amino)-; 60GCX7Y6BH; N-(alpha,alpha,alpha-Trifluoro-m-tolyl)anthranilic acid; NSC-219007; CHEBI:42638; CI-440; CN-27554; DTXCID303063; Acid, Flufenamic; 2-(3-(trifluoromethyl)anilino)benzoic acid; flufenamic acid aluminium; RefChem:388982; M01AG03; 208-494-1; Fullsafe; Nichisedan; Tecramine; Paraflu; Parlef; Flufacid; Lanceat; Plostene; Parlif; Surika; Reumajust A; Ristogen; Sastridex; Ansatin; Fluore-200; ANT-1; TVX 916; INF 1837; MFCD00002422; C.I. 440; NSC 219007; 2-(3-Trifluoromethylanilino)benzoic Acid; N-[3-(Trifluoromethyl)phenyl]anthranilic acid; 2-((3-Trifluromethyl)phenyl)aminobenzoic acid; 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID; N-(m-Trifluoromethylphenyl)-2-aminobenzoic acid; CHEMBL23588; MLS000028563; Saal-F; NCGC00016490-06; CAS-530-78-9; SMR000059027; N-(3-Trifluoromethylphenyl)-anthranilic acid; WLN: QVR BMR CXFFF; FFA; F0909-0007; Flufenamicacid; N-(.alpha.,.alpha.,.alpha.-Trifluoro-m-tolyl)anthranilic acid; Flufenaminsaeure [German]; Acido flufenamico [Italian]; FLF; CCRIS 5266; 2-[(3-Trifluromethyl)phenyl]aminobenzoic acid; N-[(3-Trifluoromethyl)phenyl]anthranilic acid; Acide flufenamique [INN-French]; Acido flufenamico [INN-Spanish]; Acidum flufenamicum [INN-Latin]; N-((m-Trifluoromethyl)phenyl)-2-aminobenzoic acid; N-[(m-Trifluoromethyl)phenyl]-2-aminobenzoic acid; N-[m-(Trifluoromethyl)phenyl]-2-aminobenzoic acid; SR-01000000241; EINECS 208-494-1; Anthranilic acid,.alpha.,.alpha.-trifluoro-m-tolyl)-; N-(.alpha.,.alpha.-Trifluoro-m-tolyl)anthranilic acid; UNII-60GCX7Y6BH; Flufenamic acid [USAN:INN:BAN:JAN]; BRN 1996069; flufenamic-acid; Prestwick_220; Arlef (TN); Spectrum_001257; 1bm7; Opera_ID_578; Prestwick0_000203; Prestwick1_000203; Prestwick2_000203; Prestwick3_000203; Spectrum2_000789; Spectrum3_001273; Spectrum4_000102; Spectrum5_000686; Etofenamate EP Impurity A; Epitope ID:613429; EC 208-494-1; Flufenamic acid (Standard); CBiol_001756; SCHEMBL17497; BSPBio_000185; BSPBio_001319; BSPBio_002866; CBDivE_012649; FLUFENAMIC ACID [MI]; KBioGR_000039; KBioGR_000424; KBioGR_002267; KBioSS_000039; KBioSS_001737; KBioSS_002268; 3-14-00-00905 (Beilstein Handbook Reference); MLS001148610; DivK1c_000581; FLUFENAMIC ACID [INN]; FLUFENAMIC ACID [JAN]; SPECTRUM1501015; SPBio_000898; SPBio_002106; FLUFENAMIC ACID [USAN]; BPBio1_000205; GTPL2447; orb1310228; FLUFENAMIC ACID [MART.]; SCHEMBL29356958; BCBcMAP01_000039; BDBM17636; HMS501N03; HY-B1221R; KBio1_000581; KBio2_000039; KBio2_001737; KBio2_002267; KBio2_002607; KBio2_004305; KBio2_004835; KBio2_005175; KBio2_006873; KBio2_007403; KBio3_000077; KBio3_000078; KBio3_002366; KBio3_002747; Anthranilic acid, N-(alpha,alpha,alpha-trifluoro-m-tolyl)-; FLUFENAMIC ACID [WHO-DD]; MSK8002; cMAP_000004; NINDS_000581; Bio1_000042; Bio1_000531; Bio1_001020; Bio2_000039; Bio2_000519; Flufenamic acid (JAN/USAN/INN); GLXC-27023; HMS1361B21; HMS1568J07; HMS1791B21; HMS1921B21; HMS1989B21; HMS2089E07; HMS2092B09; HMS2095J07; HMS2232G24; HMS3371F01; HMS3402B21; HMS3652F06; HMS3712J07; HMS3885P15; HMS5082J22; Pharmakon1600-01501015; SMSSF-0062312; HY-B1221; NSC82699; Tox21_110452; Tox21_302111; CCG-40167; EBC-04210; MSK8002-100A; NSC219007; NSC757823; s4268; SBB001140; STK985630; AKOS000265536; MSK8002-1000A; Tox21_110452_1; CS-4811; DB02266; FF23323; KS-1143; NSC-757823; Etofenamate EP Impurity A (Free Base); IDI1_000581; IDI1_033789; NCGC00016490-01; NCGC00016490-02; NCGC00016490-03; NCGC00016490-04; NCGC00016490-05; NCGC00016490-07; NCGC00016490-08; NCGC00016490-09; NCGC00016490-10; NCGC00016490-12; NCGC00023200-03; NCGC00023200-04; NCGC00023200-05; NCGC00023200-06; NCGC00023200-07; NCGC00255175-01; CN-27544; ST026563; SY014664; SBI-0051633.P002; DB-052254; 2-[3-(trifluoromethyl)anilino]-benzoic acid; AB00052198; ETOFENAMATE IMPURITY A [EP IMPURITY]; F4483; n-(a,a,a-trifluoro-m-tolyl)anthranilic acid; NS00000475; SW196528-3; UNM000001246003; 2-[3-(Trifluoromethyl)anilino]benzoic acid #; EN300-16858; o-[m-(trifluoromethyl)phenylamino]benzoic acid; 2-[(3-Trifluoromethylphenyl)amino]benzoic Acid; D01581; D97458; AB00052198-14; AB00052198_15; F358173; Q416341; 3'-Trifluoromethyldiphenylamine-2-carbox ylic acid; Flufenamic acid Solution in Acetonitrile, 100ug/mL; SR-01000000241-2; SR-01000000241-3; BRD-K44067360-001-06-3; BRD-K44067360-001-16-2; BRD-K44067360-001-29-5; BRD-K44067360-001-30-3; Flufenamic acid Solution in Acetonitrile, 1000ug/mL; Z56797275; Flufenamic acid, analytical standard, for drug analysis; Anthranilic acid, N-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-; FFA, Flufenamic acid, 3-[(2-Carboxyphenyl)amino]benzotrifluoride, 2-Carboxy-3'-(trifluoromethyl)diphenylamineSynonymes
Produits contenant Flufenamic Acid
Entreprises vendant Flufenamic Acid
NS
NINGBO SMART PHARMACEUTICAL CO.,LTDChinaDL
DILIGENT LIFE CARE PVT LTDIndiaEL
ENDOC LIFECARE PVT. LTD.IndiaSR
Suzhou Ryway Biotech Co., LtdChinaSR
Suzhou Ryway BiotechChina
(주
(주)마더스제약Republic of KoreaAC
AFINE CHEMICALS LIMITEDSB
Shaanxi Baoxin Pharmaceutical Co.,Ltd.China